Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
for the REFLEX Trial Group
S.B. Cohen, P. Emery, M.W. Greenwald for the REFLEX Trial Group Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 54 2006 2793 2806
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
J.C. Edwards, L. Szczepanski, and J. Szechinski Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2004 2572 2581
Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis
L.L. Teichmann, M. Woenckhaus, and C. Vogel Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis Rheumatology 47 2008 1256 1257
The effects of rituximab on immunocompetency in patients with autoimmune disease
R. Looney, R. Srinivasan, and L. Calabrese The effects of rituximab on immunocompetency in patients with autoimmune disease Arthritis Rheum 58 2008 5 14